Related Experiment Video
Updated: Jul 20, 2025
Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective
Ahmed Abdelhak1, Franziska Petermeier2, Pascal Benkert3
1UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Insights
This study established age-adjusted reference values for serum neurofilament light chain (sNfL), a marker of neuroaxonal injury, in healthy children and adolescents. The new sNfL Z scores improve the assessment of neurological conditions in pediatric patients.
Area of Science:
- Neurology
- Biomarkers
- Pediatrics
Background:
- Neurological conditions are a major cause of childhood disability globally.
- Serum neurofilament light chain (sNfL) is a specific biomarker for neuroaxonal injury.
- Establishing age-adjusted sNfL reference values is a research priority for managing pediatric neurological conditions.
Purpose of the Study:
- To create an age-adjusted sNfL reference range database for healthy children and adolescents.
- To validate the clinical applicability of this database in pediatric patients with neurological disorders.
Main Methods:
- sNfL concentrations were measured in 2667 healthy children/adolescents (0-22 years) from European and North American cohorts.
- Linear models and generalized additive models were used to establish age- and weight-adjusted sNfL reference percentiles and Z scores.
- The reference dataset's utility was validated in 220 pediatric patients with various neurological conditions.
Main Results:
- A reference database for sNfL was generated for ages 0-22 years, showing a decrease with age until ~10 years.
- Weight had a marginal effect on sNfL concentrations independent of age.
- Age-adjusted sNfL Z scores were significantly higher in pediatric patients with neurological conditions compared to healthy controls, with larger effect sizes than raw sNfL values.
Conclusions:
- Normative sNfL values in children and adolescents provide a basis for clinical use.
- sNfL Z scores offer a more accurate assessment of neuroaxonal damage extent in pediatric patients compared to absolute sNfL values.
Background:
Neurological conditions represent an important driver of paediatric disability burden worldwide. Measurement of serum neurofilament light chain (sNfL) concentrations, a specific marker of neuroaxonal injury, has the potential to contribute to the management of children with such conditions. In this context, the European Medicines Agency recently declared age-adjusted reference values for sNfL a top research priority. We aimed to establish an age-adjusted sNfL reference range database in a population of healthy children and adolescents, and to validate this database in paediatric patients with neurological conditions to affirm its clinical applicability.
Methods:
To generate a paediatric sNfL reference dataset, sNfL values were measured in a population of healthy children and adolescents (aged 0-22 years) from two large cohorts in Europe (the Coronavirus Antibodies in Kids from Bavaria study, Germany) and North America (a US Network of Paediatric Multiple Sclerosis Centers paediatric case-control cohort). Children with active or previous COVID-19 infection or SARS-CoV-2 antibody positivity at the time of sampling, or a history of primary systemic or neurological conditions were excluded. Linear models were used to restrospectively study the effect of age and weight on sNfL concentrations. We modelled the distribution of sNfL concentrations as a function of age-related physiological changes to derive reference percentile and Z score values via a generalised additive model for location, scale, and shape. The clinical utility of the new reference dataset was assessed in children and adolescents (aged 1-19 years) with neurological diseases (epilepsy, traumatic brain injury, bacterial CNS infections, paediatric-onset multiple sclerosis, and myelin oligodendrocyte glycoprotein antibody-associated disease) from the paediatric neuroimmunology clinic at the University of California San Francisco (San Francisco, CA, USA) and the Children's Hospital of the University of Regensburg (Regensburg, Germany).
Findings:
Samples from 2667 healthy children and adolescents (1336 [50·1%] girls and 1331 [49·9%] boys; median age 8·0 years [IQR 4·0-12·0]) were used to generate the reference database covering neonatal age to adolescence (target age range 0-20 years). In the healthy population, sNfL concentrations decreased with age by an estimated 6·8% per year until age 10·3 years (estimated multiplicative effect per 1 year increase 0·93 [95% CI 0·93-0·94], p<0·0001) and was mostly stable thereafter up to age 22 years (1·00 [0·52-1·94], p>0·99). Independent of age, the magnitude of the effect of weight on sNfL concentrations was marginal. Samples from 220 children with neurological conditions (134 [60·9%] girls and 86 [39·1%] boys; median age 14·7 years [IQR 10·8-16·5]) were used to validate the clinical utility of the reference Z scores. In this population, age-adjusted sNfL Z scores were higher than in the reference population of healthy children and adolescents (p<0·0001) with higher effect size metrics (Cohen's d=1·56) compared with the application of raw sNfL concentrations (d=1·28).
Interpretation:
The established normative sNfL values in children and adolescents provide a foundation for the clinical application of sNfL in the paediatric population. Compared with absolute sNfL values, the use of sNfL Z score was associated with higher effect size metrics and allowed for more accurate estimation of the extent of ongoing neuroaxonal damage in individual patients.
Funding:
Swiss National Science Foundation, US National Institutes of Health, and the National Multiple Sclerosis Society.
